EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan

Norio Chihara, Justin Lee, Jeffrey C Yu, Naoki Numajiri, Tatsuro Misu

Neurology and Therapy · 2026-08 · 15 (4) · 1539-1555

DOI: 10.1007/s40120-026-00938-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 25.04.2026. Verfasst von Norio Chihara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Adherence, treatmentClaims analysisComplement C5 inhibitorCompliance, treatmentEculizumabInterleukin-6 receptor inhibitorNeuromyelitis optica spectrum disorderRavulizumabSatralizumabTreatment persistence

Autor:innen und Institutionen

  • Division of Neurology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
  • Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA, USA.
  • Alexion Pharma GK, Tamachi Station Tower N, 3-1-1, Shibaura, Minato-ku, Tokyo, 108-0023, Japan. naoki.numajiri@alexion.com.
  • Department of Neurology, Tohoku University Hospital, 1-1 Seiryomachi, Aoba Ward, Sendai, Japan.

Förderung

  • Alexion, AstraZeneca Rare Disease

Zitieren

APA

Chihara, N., Lee, J., Yu, J. C., Numajiri, N., & Misu, T. (2026). Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan. Neurology and Therapy, 15(4), 1539-1555. https://doi.org/10.1007/s40120-026-00938-8

Vancouver

Chihara N, Lee J, Yu JC, Numajiri N, Misu T. Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan. Neurology and Therapy. 2026;15(4):1539-1555. doi:10.1007/s40120-026-00938-8

BibTeX
@article{Chihara2026,
  author = {Chihara, Norio and Lee, Justin and Yu, Jeffrey C and Numajiri, Naoki and Misu, Tatsuro},
  title = {Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan},
  journal = {Neurology and Therapy},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {1539--1555},
  doi = {10.1007/s40120-026-00938-8}
}
Kostenlos starten →